Fig. 2From: HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, ChinaThe therapy regimens of ART participants in this study. ATV/r atazanavir/r, NFV/r nelfinavir plus ritonavir, LPV/r lopinavir plus ritonavir, 3TC lamivudine, ABC abacavir, AZT zidovudine, D4T stavudine, DDI didanosine, FTC emtricitabine, TDF tenofovir, EFV efavirenz, ETR etravirine, NVP nevirapineBack to article page